SANXING(SH:601567) Xin Lang Cai Jing·2025-08-22 02:43Core Insights - Samsung Medical (601567.SH) reported a total operating revenue of 7.972 billion yuan for the first half of 2025, marking an increase of 9.75 billion yuan compared to the same period last year, achieving a 4-year consecutive growth with a year-on-year increase of 13.93% [1] - The net profit attributable to shareholders reached 1.230 billion yuan, an increase of 797.24 million yuan from the same period last year, achieving a 3-year consecutive growth with a year-on-year increase of 6.93% [1] - The company reported a net cash outflow from operating activities of 59.26 million yuan [1] Financial Ratios - The latest debt-to-asset ratio stands at 46.62%, a decrease of 1.17 percentage points from the previous quarter [3] - The latest gross profit margin is 28.97%, an increase of 0.07 percentage points from the previous quarter [4] - The latest return on equity (ROE) is 10.11% [4] - The diluted earnings per share (EPS) is 0.87 yuan, an increase of 0.06 yuan from the same period last year, achieving a 3-year consecutive growth with a year-on-year increase of 7.41% [4] - The latest total asset turnover ratio is 0.33 times, and the inventory turnover ratio is 1.38 times [4] Shareholder Information - The number of shareholders is 29,000, with the top ten shareholders holding 918 million shares, accounting for 65.03% of the total share capital [5]